AR and breast carcinoma: AR expression is associated with poor response to neoadjuvant chemotherapy in ER-positive breast cancer [28], and patients with AR-positive or LAR breast cancer also have poor pathological clinical response to neoadjuvant chemotherapy when compared to other TNBC [29, 30].